阿斯利康的Etcamah作为一线乳腺癌治疗药物在后期试验中失败

2026-09-12 06:04

AstraZeneca's (AZN) recently approved Etcamah (camizestrant) failed in a phase 3 trial as a first-line treatment in combination with Pfizer's (PFE) Ibrance (palbociclib) for HR+, HER2- breast cancer.
Results from the SERENA-4 trial showed that the combination did not improve progression-free survival vs. Ibrance + the aromatase inhibitor Arimidex (anastrozole) with statistical significance. The trial enrolled about 1,400 individuals with no systemic treatment for metastatic disease.
Etcamah is also in two other phase 3 trials, CAMBRIA-1 and CAMBRIA-2, that have enrolled about 10,000 patients examining the drug in individuals with intermediate and high risk of recurrence in the adjuvant setting as monotherapy, in combination with CDK4/6 inhibitors, and following CDK4/6 inhibitor treatment.
Etcamah received accelerated approval earlier in September for those with breast cancer who possess an estrogen receptor-1 (ESR1) mutation, which can be discovered during aromatase inhibitor and CDK 4/6 inhibitor therapy.

More on AstraZeneca